Abstract
Autologous hematopoietic transplantation is now a well-established treatment for many malignant and nonmalignant disorders. Mobilization and collection of hematopoietic cells from peripheral blood with faster hematopoietic recovery has made this approach the treatment of choice for patients with relapsed lymphoma and standard of care for treatment of multiple myeloma. Of 50 000-60 000 hematopoietic stem cell transplants performed worldwide annually, 35 000-40 000 are autologous. With improvement in transplantation techniques, there are a growing number of autoHCT survivors as well as several late effects of transplantation that may account for decrease in long-term survival for recipients of autologous transplants.
| Original language | English (US) |
|---|---|
| Title of host publication | Blood and Marrow Transplantation Long Term Management |
| Subtitle of host publication | Prevention and Complications |
| Publisher | Wiley-Blackwell |
| Pages | 31-42 |
| Number of pages | 12 |
| ISBN (Electronic) | 9781118473306 |
| ISBN (Print) | 9781118473405 |
| DOIs | |
| State | Published - Sep 9 2013 |
Keywords
- Chemotherapy-induced cardiomyopathy
- Cognitive dysfunction
- Endocrine dysfunction
- Pulmonary toxicity
- Secondary malignancy
- Therapy-related acute myeloid leukemia
ASJC Scopus subject areas
- General Medicine